Dazhong Dental, C-MER Eye Care, Zhonghua Dental, Megagen, and Meiya Optoelectronics release financial reports; oral care brand "Canban" parent company submits application to Hong Kong Exchanges and C…

Dazhong Dental 2025: Net Profit Attributable to Shareholders of the Parent Company Falls 32.8%, Annual Dividend Payout of 32.98 Million Yuan

On March 31, 2026, Wuhan Dazhong Oral Medical Co., Ltd. released its 2025 annual performance announcement. The company achieved annual revenue of 372 million yuan, a year-on-year decrease of 8.7%; Net Profit Attributable to Shareholders of the Parent Company was 28.175 million yuan, a year-on-year decrease of 32.8%. Revenue from the dental implantation business was 98.4 million yuan, down 14.9% year-on-year, primarily due to a 7.9% decrease in patient visits; revenue from the orthodontics business was 70.643 million yuan, down 4.7% year-on-year. As of December 31, 2025, the total number of the company's medical institutions reached 92. The board of directors proposed a final dividend of 0.668 yuan per share, with a total cash dividend of 32.9852 million yuan.

C-MER Medical 2025: Dental Business Annual Revenue of 507 Million HKD, Annual Patient Visits Increase 13.9% Year-on-Year

On March 27, 2025, C-MER Medical released its 2025 annual performance report. The company achieved revenue of 1.947 billion HKD, a year-on-year increase of 1.80%; net profit attributable to equity holders was 100 million HKD, turning a profit from a loss. The dental business generated revenue of 507 million HKD, with annual patient visits increasing by 13.9% year-on-year, but revenue per chair decreased by 20.2%. Mainland China dental revenue was 460 million HKD, a slight decrease of 1.0% year-on-year, and segment profit dropped from 96.1 million HKD to 67.5 million HKD, mainly affected by the ramp-up period of new clinics. Hong Kong medical business revenue increased by 5.2% year-on-year to 949 million HKD, with its proportion rising to 48.8%. The board of directors proposed a final dividend of 2.0 HK cents per share and a special dividend of 1.0 HK cent per share.

Zhonggang Dental 2025: Revenue of 59.1752 Million Yuan Increases Over 60%, Gross Profit Margin Rises to 48.78%

In 2025, Zhonggang Dental achieved operating revenue of 59.1752 million yuan, a year-on-year increase of 61.71%; net profit attributable to shareholders of the listed company was 3.069 million yuan, a year-on-year increase of 47.33%. The company's net profit after deducting Non-recurring Gains and Losses was 3.6708 million yuan, an increase of 774.08% compared to the same period last year. The gross profit margin rose from 42.19% to 48.78%. As of the end of 2025, the company's total assets reached 61.7715 million yuan, with an asset-liability ratio of 30.12%. As of March 30, 2026, Zhonggang Dental cumulatively managed 41 dental clinics, of which it controlled 35 and held equity in 6.

MegaGen 2025: Operating Profit Doubles to 58.1 Billion KRW

On March 31, 2026, MegaGen Implant released its 2025 annual report. The report shows that the company's annual operating revenue was 280.736 billion KRW (approximately 1.268 billion yuan), a year-on-year decrease of 7.89%. However, Operating Profit reached 58.097 billion KRW (approximately 262 million yuan), a year-on-year increase of 102.1%. Net profit for 2025 was 43.2 billion KRW (approximately 195 million yuan), an increase of about 42% year-on-year. The profit growth was attributed to effective cost control and product portfolio optimization, with revenue from dental implant and related products accounting for approximately 77.2%. As of the end of 2025, the company's total assets were 452.349 billion KRW, with an asset-liability ratio of about 46.2%.

Meiya Optoelectronics 2025: Medical Equipment Business Revenue of 454 Million Yuan, Down 9.75% Year-on-Year

On March 31, 2026, Meiya Optoelectronics released its 2025 annual report. The report shows that revenue from the medical equipment business was 454 million yuan, a year-on-year decrease of 9.75%, accounting for 18.87% of total revenue. The company achieved annual operating revenue of 2.407 billion yuan, a year-on-year increase of 4.16%; net profit attributable to shareholders of the listed company was 719 million yuan, a year-on-year increase of 10.77%. The company launched the oral imaging AI agent "Meiya Imaging Engine" and promoted the digital transformation of oral diagnosis and treatment. Overseas revenue was 564 million yuan, an increase of 9.78% year-on-year, with its proportion rising to 23.42%. At the time of reporting, the company plans to distribute a cash dividend of 7.00 yuan per 10 shares to all shareholders.

Zhenghai Bio 2025: Dental Restoration Membrane Revenue of 136 Million Yuan, Down 15.8% Year-on-Year

On March 31, 2026, Zhenghai Bio released its 2025 annual report. During the reporting period, the company achieved operating revenue of 364 million yuan, a year-on-year increase of 0.25%; net profit attributable to shareholders of the listed company was 82.4101 million yuan, a year-on-year decrease of 38.79%. Revenue from dental restoration membranes was 136 million yuan, a year-on-year decrease of 15.82%, with its proportion of operating revenue dropping to 37.46%. R&D expenses increased by 45.05% year-on-year to 57.326 million yuan, mainly due to the advancement of various R&D projects according to plan. The company initiated the establishment of the "China Dental Disease Prevention Foundation Oral Regenerative Medicine Research Special Fund" to support related research and technology transfer.

Kangtuo Medical 2025: Completes Acquisition of Xi'an Salamander Biotechnology, Oral Business Revenue of 3.4351 Million Yuan

In 2025, Kangtuo Medical completed the acquisition of Xi'an Salamander Biotechnology, acquiring a 55.4999% equity stake for 84.9825 million yuan, successfully entering the oral field and building a solution covering the entire dental implantation process. The company achieved operating revenue of 351 million yuan, a year-on-year increase of 9.05%; net profit attributable to shareholders of the listed company was 98.7035 million yuan, a year-on-year increase of 11.66%. Revenue from the oral business was 3.4351 million yuan, marking a breakthrough in the initial layout. Among the main businesses, revenue from neurosurgical PEEK material and titanium material products reached 304 million yuan, accounting for 89.07% of main business revenue. R&D investment in 2025 was 31.9816 million yuan, accounting for 9.11% of operating revenue.

China Oral Industry Group Holdings Limited 2025: Revenue Down 27.4%, Dental Clinic Business Segment Turns from Loss to Profit

On December 31, 2025, China Oral Industry Group Holdings Limited released its annual performance announcement. During the reporting period, the company achieved revenue of 168 million yuan, a year-on-year decrease of 27.4%; the annual loss was approximately 42.717 million yuan, expanding by 159.9% compared to 2024. The dental clinic business achieved revenue of approximately 24.271 million yuan, an increase of 7.7% year-on-year, and achieved a profit of 297,000 yuan for the first time. The total asset value was 166 million yuan, and total liabilities were 69.527 million yuan. Revenue from the inflatable products business was approximately 105 million yuan, a year-on-year decrease of 40.1%, mainly due to increased tariffs and reduced orders from the US market. The company plans to acquire the entire registered capital of Shishi Xinsuochenglong Weaving Co., Ltd. for a total consideration of 21.6 million HKD.

Dentis 2025: Net Profit Turns from Profit to Loss, Bad Debt Provisions Account for About 23% of Accounts Receivable

South Korean oral medical equipment manufacturer Dentis (261200.KQ) released a revised announcement for its 2025 annual business report, showing that net profit turned from profit to loss, with a loss of 5.904 billion KRW (approximately 27 million yuan), compared to a profit of 4.521 billion KRW in the same period of 2024. The company's 2025 operating revenue was 92.689 billion KRW, a slight decrease of about 2.0% from 94.588 billion KRW in 2024. The balance of bad debt provisions was 19.674 billion KRW, accounting for 23.1% of Accounts Receivable. Despite overall performance pressure, the company continued its overseas market expansion, adding subsidiaries in Thailand, Vietnam, and Australia, and plans to strengthen customer credit assessment and risk management in 2026 to improve balance sheet health.

Parent Company of Oral Care Brand "Canban" Files for Hong Kong Exchanges and Clearing Limited Listing: Over 3 Billion in Sales Expenses in Three Years, 130 Million Yuan Dividend Paid Before IPO

On March 27, 2026, Shenzhen Xiaokuo Technology Co., Ltd., the parent company of the oral care brand "Canban," formally submitted a listing application to the main board of Hong Kong Exchanges and Clearing Limited, planning to become the "first oral care stock" on the Hong Kong stock market. The prospectus shows that from 2023 to 2025, Xiaokuo Technology's revenues were 1.096 billion yuan, 1.369 billion yuan, and 2.499 billion yuan, respectively; during the same period, cumulative sales and distribution expenses were approximately 3.054 billion yuan, with marketing expenses of 570 million yuan, 720 million yuan, and 1.374 billion yuan, respectively. Despite revenue growth, Xiaokuo Technology's net profit attributable to shareholders of the parent company turned from profit to loss, recording a loss of -18.251 million yuan in 2025. Before submitting the IPO application, the company declared and paid a dividend of 130 million yuan. Additionally, the company's online sales accounted for 80.3% of total sales. At the time of reporting, the company has not disclosed the total amount of funds planned to be raised in this IPO.

Tong Ce Medical Responds to Regulatory Inquiry: Plans to Acquire 4 Eye Care Companies for 600 Million Yuan, Core Target's Value Appreciation Exceeds 12 Times

On April 2, 2026, Tong Ce Medical acquired 100% equity of four eye care companies, including Hangzhou Cunji Glasses, for 600 million yuan. The net assets of Hangzhou Cunji Glasses on the valuation reference date were 50.8779 million yuan, with an appraisal value appreciation rate of 1282.14%. The estimated revenue for 2025 is 153 million yuan, with a Net Profit Attributable to Shareholders of the Parent Company of 55.5848 million yuan. The counterparty to the transaction committed that the cumulative net profit from 2026 to 2028 will not be less than 180 million yuan. This acquisition is an important step for Tong Ce Medical in implementing its "Oral + Ophthalmology" dual-drive strategy, which is expected to help reduce customer acquisition costs and improve operational efficiency in the future.

Shining3D Tech Co., Ltd.'s Beijing Stock Exchange IPO Review Suspended Due to Expired Financial Reports, Will Apply for Resumption After Updating Audit

On March 31, 2026, Shining3D Tech Co., Ltd. suspended its application for the public offering of shares to unspecified qualified investors and listing review, due to the impending expiration of the validity period of the financial reports cited in the application documents. The company stated that it will apply to resume the review as soon as possible upon completion of the relevant work. The 2025 annual review report shows that the company achieved annual operating revenue of 1.575 billion yuan, a year-on-year increase of 31.03%; Net Profit Attributable to Shareholders of the Parent Company reached 425 million yuan, an increase of approximately 100% year-on-year. At the time of reporting, Shining3D's stock will continue to be suspended from trading.

Two Private Equity (PE) Investment Firms Make Strategic Investment in US Dental Lab Platform, Covering 16 Labs Across 12 States

On March 31, 2026, Private Equity (PE) investment firms LongueVue Capital and Swaney Group Capital completed a Strategic Investment in the US dental lab platform Apex Dental Laboratory Group, with specific amounts undisclosed. Apex operates 16 dental labs across 12 US states, with approximately 400 employees, providing 100% US-made end-to-end restoration solutions, including crowns, bridges, full-arch restorations, dentures, etc. The new executive chairman, Bill Braun, previously served as CEO of DDS Lab, one of the largest dental lab platforms in the US, and is expected to drive Apex's value creation plan.

Japanese Dentistry: Anesthetic Shortage Continues with Limited Supply, Number of Dental Technicians Decreases by 5500 in 24 Years

On March 25, 2026, the Japanese dental industry faces dual challenges of anesthetic shortages and talent drain. Since last September, major dental anesthetic manufacturer GC Showa Pharmaceutical's production has stalled due to equipment failure, leading to treatment delays. Meanwhile, the number of dental technicians has decreased by approximately 5500 over the past 24 years, with an actual employment rate of only 25.4%. Low insurance reimbursement rates are the core reason for technician attrition, with 38.8% of dental technicians having an annual income below 3 million yen. Japan's Ministry of Health, Labour and Welfare is studying the use of digital transformation to alleviate this situation, aiming to attract talent back and improve the working environment for technicians.

Per-Patient Payments + Gift Cards to Induce Patients, Texas Sues Dentists and Multiple Associated Clinics

On March 31, 2026, Texas Attorney General Ken Paxton filed a lawsuit against dental clinics for defrauding the Texas Medicaid program, alleging that several dentists and their associated clinics paid third parties based on patient numbers and induced Medicaid beneficiaries to seek treatment through cash, gift cards, etc., subsequently submitting claims influenced by kickbacks. According to the announcement from the Texas Attorney General's Office, some patients underwent high-risk dental procedures lacking medical necessity, with the victim group including children. Paxton filed the case based on the Texas Health Care Program Fraud Prevention Act, requesting the court to order the defendants to pay full compensation and bear legal liability.

Medical Insurance Fund Supervision Detailed Rules Take Effect from April, Clarifying Standards for Identifying Induced Medical Visits

On April 1, 2026, the "Detailed Implementation Rules for the Regulations on the Supervision and Administration of the Use of Medical Security Funds" officially took effect. The "Detailed Rules" clarify situations of fraud against insurance funds by designated medical institutions and insured individuals, marking the entry of Medical Insurance Fund supervision into a new stage of intelligent, whole-process, and all-domain supervision. For the first time, it establishes violation identification standards under Diagnosis Related Groups (DRG)/Diagnosis-Intervention Packet (DIP) payment models and provides three methods for calculating fund losses. Furthermore, it lists multiple illegal acts and corresponding penalties for designated medical institutions and individuals committing insurance fraud. The detailed rules establish a dual protection mechanism, allowing for no administrative penalties for minor violations. Since implementation, medical insurance departments at all levels have recovered approximately 120 billion yuan in medical insurance funds.

2026 QS World University Rankings by Subject - Dentistry: 8 Chinese Universities Ranked, Sichuan University Enters Global Top 10 for First Time

On March 30, 2026, QS released the 2026 World University Rankings by Subject for Dentistry. A total of 8 Chinese universities were ranked, with Sichuan University entering the global top 10 for the first time, ranking 10th, setting a historical best performance for a mainland Chinese university on this list. The University of Hong Kong ranked 2nd globally, continuing to hold the top position in Asia. Wuhan University ranked 33rd, and Peking University ranked 45th, both entering the global top 50. Additionally, Shanghai Jiao Tong University, Sun Yat-sen University, Zhejiang University, Southern Medical University, and others were ranked in the 51–150 range, reflecting the overall expansion of dental education in China. The QS ranking is based on five core indicators: academic reputation, employer reputation, citations per paper, H-index, and international research network.

DentScribe Launches AI Treatment Coordinator Notes, Transforming Front Desk Conversations into Operational Insights

On April 1, 2026, the US dental artificial intelligence platform DentScribe launched "AI Treatment Coordinator Notes," aiming to transform communication between clinic front desks and patients into structured internal records and operational insights. This workflow utilizes agent AI foundation to capture conversations between patients and coordinators/business teams, organizing them into operationally relevant content such as treatment plan reviews and financial discussions, addressing issues like inconsistent patient handoffs and lack of records for financial communications. DentScribe was founded in 2023 and is headquartered in Sunnyvale, California, USA. It has integrated this feature into its platform, supporting integration with mainstream practice management systems.

Mesosil Antimicrobial Dental Biomaterial Receives FDA Clearance, Controlled-Release Technology May Reduce Secondary Caries Risk by 80%

On March 29, 2026, startup Mesosil announced that its developed antimicrobial dental biomaterial has received 510(k) clearance from the US FDA. The material utilizes nanotechnology, aiming to continuously release antimicrobial agents at the interface between the tooth and the filling, potentially reducing the incidence of secondary caries by approximately 80%. Mesosil's core technology is based on porous silica particles, enabling controlled release of antimicrobial agents. The company will focus on scaling up production and establishing global industry partnerships to promote the commercial application of anti-infective restorative materials. Mesosil was founded in 2018, and its technology originated from the founder's research at the University of Toronto.

University of Malaya Becomes World's First "Dental Education Centre" Accredited by Royal College of Surgeons of England

The Faculty of Dentistry at the University of Malaya was officially awarded accreditation by the Royal College of Surgeons of England in London, becoming the world's first institution accredited as a "Dental Education Centre." This accreditation covers 8 doctoral programs at the faculty, including Orthodontics, Paediatric Dentistry, Prosthodontics, Periodontology, and Dental Public Health. The accreditation ceremony was presented by Dr. Charlotte Eckhardt, Head of the Faculty of Dental Surgery at RCS England, marking the University of Malaya's commitment to meeting international benchmarks in education, research, and clinical training. At the time of reporting, the University of Malaya stated that this accreditation opens doors for in-depth collaboration between the two parties in academic exchange, clinical training, and research innovation.

West China School of Stomatology Research: Higher Parent-Child Relationship Closeness Correlates with Better Clear Aligner Therapy Adherence

Research from West China Hospital of Stomatology shows that the closeness and conflict levels in parent-child relationships are significant predictors of clear aligner therapy adherence in children and adolescents. The study included 124 patients aged 6 to 18. Data indicated that patients with high closeness were 2.2 times more likely to achieve good adherence than those with low closeness, while in high-conflict parent-child relationships, the likelihood of good adherence was only 0.3 times that of the low-conflict group. Among adherence indicators, appointment follow-up scored the highest, while chewies usage scored the lowest, revealing weak points in management. The study suggests that Orthodontists assess patients' parent-child relationships before treatment to develop personalized adherence management plans.